Genetic Modification of Mesenchymal Stem Cell to Overexpress CXCR4 Enhances Treatment Efficacy for Brain Injury After Cardiopulmonary Resuscitation
Open Access
- 22 September 2025
- journal article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (9) , e70621
Abstract
Aim: To investigate whether genetically modifying human umbilical cord‐derived mesenchymal stem cells (MSC) to overexpress the CXCR4 receptor can enhance their therapeutic efficacy for treating brain injury following cardiac arrest (CA). Methods: MSC were engineered to overexpress CXCR4 (CXCR4‐MSC) via lentiviral transduction. The migration capacity of these cells was tested using in vitro chemotaxis assays. In a rat model of CA/CPR, the homing ability of CXCR4‐MSC to the brain was tracked in vivo, and their therapeutic effects on neuronal death and neurological recovery were assessed. The role of exosomes and their impact on key proteins (NLRP3, ASC, GSDMD) in the pyroptosis pathway was also investigated. Result: CXCR4 overexpression significantly enhanced the migration of MSC in vitro and their homing to injured brain tissue in vivo. Treatment with CXCR4‐MSC markedly reduced neuronal death and improved neurological recovery in resuscitated rats. This was accompanied by decreased expression of NLRP3. Furthermore, exosomes derived from CXCR4‐MSC were found to suppress pyroptosis‐related proteins (NLRP3/ASC/GSDMD) in post‐CPR neurons, an effect that was reversed upon exosome inhibition. Conclusion: Genetic modification to overexpress CXCR4 enhances the therapeutic efficacy of MSC for CA‐induced brain injury by promoting their migration to the brain via the CXCL12/CXCR4 axis. A key mechanism of this protection is exosome‐mediated inhibition of neuronal pyroptosis.Keywords
Funding Information
- Natural Science Basic Research Program of Shaanxi Province (2023‐JC‐ZD‐52)
This publication has 29 references indexed in Scilit:
- Genetic modification to induce CXCR2 overexpression in mesenchymal stem cells enhances treatment benefits in radiation-induced oral mucositisCell Death & Disease, 2018
- Resveratrol augments therapeutic efficiency of mouse bone marrow mesenchymal stem cell‐based therapy in experimental autoimmune encephalomyelitisInternational Journal of Developmental Neuroscience, 2016
- The Life and Fate of Mesenchymal Stem CellsFrontiers in Immunology, 2014
- CXC-Chemokine Receptor 4 Antagonist AMD3100 Promotes Cardiac Functional Recovery After Ischemia/Reperfusion Injury via Endothelial Nitric Oxide Synthase–Dependent MechanismCirculation, 2013
- Genetic Modification of Mesenchymal Stem Cells to Overexpress CXCR4 and CXCR7 Does Not Improve the Homing and Therapeutic Potentials of These Cells in Experimental Acute Kidney InjuryStem Cells and Development, 2012
- Targeted Intra-arterial Transplantation of Stem Cells to the Injured CNS is more Effective than Intravenous Administration: Engraftment is Dependent on Cell Type and Adhesion Molecule ExpressionCell Transplantation, 2012
- Intravenous hMSCs Improve Myocardial Infarction in Mice because Cells Embolized in Lung Are Activated to Secrete the Anti-inflammatory Protein TSG-6Cell Stem Cell, 2009
- Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult ratsBrain Research, 2008
- Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brainJournal of Neuroimmunology, 2008
- A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrowBlood, 2004